nference, a Cambridge, MA-based provider of an artificial intelligence (AI)-powered life sciences software platform, completed an $11m Series A financing.
The round was led by Matrix Partners, with participation from existing investor Matrix Capital Management.
The company intends to use the funds to further develop its AI and R&D platforms, expand scientific operations in Cambridge MA and establish nference Labs in Bangalore, India.
Founded by Murali Aravamudan and Venky Soundararajan, Ph.D., nference works with pharmaceutical partners to solve some of today’s biggest challenges in drug discovery and clinical research. This includes the identification of emerging targets and signaling pathways for disease processes with unmet need, stratification of patients in clinical trials, and prioritization of life-cycle opportunities for drugs in development. At the core of these collaborations, the nference AI platform plays a central role in augmenting the scientists’ abilities to generate holistic data-driven and unbiased hypotheses in a rapid manner.